Gerresheimer AG, glass supplier to the pharma and healthcare industry worldwide, began financial year 2014 with a solid start. “I am satisfied with our performance in the first quarter of 2014. Our expectation is unchanged that we will meet our targets for 2014. We will continue to invest in promising projects in Europe, the Americas and emerging markets to lay the basis for further profitable growth,” said Uwe Röhrhoff, CEO of Gerresheimer AG. Gerresheimer generated revenues of EUR 297.5m in the first quarter of financial year 2014 (1 December 2013 to 30 November 2014), marking 0.3% revenue growth on the prior-year quarter. At constant exchange rates, revenues came to EUR 304.2m, representing growth of 3.2%. As expected, the Primary Packaging Glass and Life Science Research (laboratory glassware) divisions experienced a decline in demand during the first month of the first quarter due to destocking by a number of North American pharmaceutical customers. Demand for cosmetic glass was likewise slow at the beginning of the first quarter. There were already clear signs of improvement by the end of the quarter. Revenues went up substantially on customer-specific drug-delivery devices such as insulin pens, inhalers, prefillable syringe systems and pharmaceutical plastic packaging. Revenues up 0.3% to EUR 297.5m (+3.2% at constant exchange rates); Adjusted EBITDA rises 3.3% to EUR 47.6m (EUR 49.1m at constant exchange rates); Net income grows by 0.8% to EUR 10.3m; Adjusted earnings per share up 5.6% to EUR 0.38; Guidance for financial year 2014 confirmed.
